Bms-907351
Stage IV Penile Cancer AJCC v8
National Cancer Institute (NCI)Phase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Stage IV Penile Cancer AJCC v8 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab National Cancer Institute (NCI) | Phase 2 | B |
Ipilimumab National Cancer Institute (NCI) | Phase 2 | B |
Dna Plasmid-Encoding Interleukin-12/Hpv Dna Plasmids Therapeutic Vaccine Medi0457 M.D. Anderson Cancer Center | Phase 2 | CCC |
Durvalumab M.D. Anderson Cancer Center | Phase 2 | CCC |
Plasmid Encoded Il-12 M.D. Anderson Cancer Center | Phase 2 | CCC |
Same molecule, other indications
Bms-907351 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →